作为近年白酒行业"备受关注"听花酒的母公司，ST春天在去年并没能依靠这一"天价白酒"实现扭亏摘 帽，反而因为去年第四季度"突击增收"遭到质疑。不过在一系列争议过后，南都湾财社-酒水新消费指 数课题组记者发现，今年一季度听花酒开始发力。根据同期披露的一季报数据，ST春天今年一季报营 收为8355.9万元，同比下降1.11%，但是归母净利润为891.8万元，同比实现扭亏为盈。 那么，在白酒深度调整期且酒水消费价格带出现变化的大背景下，听花酒能否带着ST春天打赢保壳之 战并实现"脱星摘帽"，这成为酒水年报季中备受关注的热点之一。但是在酒水深度调整的大背景以及听 花酒的市场状况来看，ST春天可能更依靠传统业务来"保壳"。 卖酒一个月收入顶半年，去年"精准踩线"被质疑 据南都湾财社记者了解，ST春天被"上星"的主要原因，与其去年第四季度"突击增收"有关。 ST春天在今年第一季度遭遇了"冰火两重天"。 近日，青海春天（即ST春天）先后披露2024年报和今年一季报，2024年报数据来看，该公司去年营收 为2.7亿元，同比上涨26.36%；扣除与主营业务无关的业务收入和不具备商业实质的收入后，该公司营 收达2.24亿元，年内 ...

Core Viewpoint - The A-share ST sector is experiencing a strong performance, with over 40 stocks including *ST Jingang, *ST Tianwei, *ST Bodao, *ST Gaohong, *ST Zhongdi, *ST Chuntian, and ST Ruihe hitting the daily limit up [1] Group 1 - The ST sector is showing significant strength in the A-share market [1] - More than 40 stocks in the ST category have reached their daily trading limit [1]

Financial Performance - In 2024, the company achieved total revenue of 270 million yuan, a year-on-year increase of 26.36% [2][3] - The net profit attributable to shareholders was a loss of 199.77 million yuan, an improvement from a loss of 268.65 million yuan in the previous year [2][3] - The net profit excluding non-recurring items was a loss of 161.57 million yuan, compared to a loss of 243.67 million yuan in the previous year [2][3] - The net cash flow from operating activities was 80.97 million yuan, a significant increase of 238.56% year-on-year [2][3] Key Ratios - The basic earnings per share for 2024 was -0.34 yuan, with a weighted average return on equity of -17.26% [2][3] - The company's price-to-earnings ratio (TTM) is approximately -8.71 times, while the price-to-book ratio (LF) is about 1.68 times, and the price-to-sales ratio (TTM) is around 6.41 times [2][3] Asset and Liability Changes - As of the end of 2024, the company's net assets attributable to shareholders decreased by 18.38% compared to the previous year [3] - Inventory decreased by 41.44%, while cash and cash equivalents increased by 20.29% [51] - Contract liabilities increased by 106.8%, while lease liabilities decreased by 69.72% [54] Research and Development - The company invested 14.96 million yuan in research and development in 2024, a year-on-year increase of 28.54%, representing 5.54% of total revenue [61] Shareholder Structure - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 32.13% of the shares, with significant pledges on their holdings [65] - New shareholders include Hu Zhenmin, Zhu Qiulian, Zhang Qian, and Ye Lingxiang, replacing previous shareholders [66]

Core Insights - A-share listed companies demonstrated strong resilience in 2024, with total operating revenue reaching 62.33 trillion yuan, a year-on-year increase of 0.57%, and net profit attributable to shareholders of 5.06 trillion yuan, up 1.05% [1][2] - The growth was primarily driven by advancements in artificial intelligence (AI) technology, which significantly boosted demand in sectors such as GPU, PCB, and storage chips [2][3] - Despite overall growth, non-financial companies faced challenges, with a slight decline in revenue and a notable drop in net profit [1][3] Financial Performance - Among the 5402 listed companies, 4029 reported positive earnings, with 548 companies achieving over 100% growth in net profit [2] - The chemical company Zhengdan achieved a remarkable 119-fold increase in net profit, driven by soaring TMA prices due to supply-demand imbalances [2][3] - The semiconductor sector saw significant profit increases, with companies like Zhaoyi Innovation and Weir Shares reporting net profit growth of 584.21% and 498.11%, respectively [3] Sector Analysis - The AI sector is identified as a key growth driver, with companies in the GPU, PCB, and optical module industries experiencing substantial performance improvements [2][3] - The consumer electronics market is also rebounding, with a reported 5.6% year-on-year increase in smartphone shipments in China [3][4] International Expansion - A total of 3653 listed companies reported overseas revenue of 9.43 trillion yuan, accounting for approximately 20% of their total revenue [6][7] - Companies like Luxshare Precision and BYD achieved over 100 billion yuan in overseas revenue, with notable growth in emerging markets [6][7] - The internationalization strategies include local market investments and partnerships, particularly in Africa and the Middle East [7][8] Challenges and Losses - Despite overall positive performance, 124 companies reported net losses exceeding 1 billion yuan, with the real estate sector being particularly affected [9][10] - Vanke A led the loss rankings with a staggering 494.78 billion yuan loss, highlighting the difficulties faced in the real estate market [9][10] - The energy sector, including solar and lithium companies, also reported significant losses due to overcapacity and intensified competition [10] Regulatory Environment - The introduction of stricter delisting regulations is expected to normalize the delisting process, with 52 companies delisted in 2024 [11][12] - New rules include higher thresholds for financial delisting criteria, aiming to enhance market stability and protect investor interests [11][12]

Core Viewpoint - Qinghai Spring (600381) has shown significant resilience in its operations, with a notable increase in revenue and a positive shift in profitability, leading to a strong market response reflected in its stock price surge on April 30 [1][4]. Financial Performance - In 2024, the company reported total revenue of 270 million, representing a nearly 30% year-on-year growth [5]. - The net cash flow from operating activities reached 81 million, marking the best level since 2018 [5]. - The first quarter of 2025 saw revenue of approximately 84 million, achieving a new high over the last four quarters, with net profit turning positive after a series of losses since 2020 [9]. Strategic Initiatives - The company is actively addressing intensified industry competition by increasing product promotion and market expansion efforts in the liquor and health sectors, with sales expenses amounting to 147 million, accounting for 54.65% of total revenue [8]. - Qinghai Spring has made significant advancements in its liquor segment, obtaining patents for innovative brewing methods and health-oriented product formulations, which are expected to enhance product quality and market appeal [8]. Future Outlook - The company plans to focus on promoting sales of health products such as Cordyceps and lung health tablets in 2025, while continuing to drive innovation in the liquor sector [10]. - Qinghai Spring aims to respond to national initiatives for developing emerging industries and enhancing production capabilities, seeking to establish new business segments for sustainable growth [10].

Core Viewpoint - The white liquor industry is experiencing a significant slowdown in growth, with many companies reporting declining revenues and profits, indicating a challenging market environment [1][12][18]. Group 1: Industry Performance - As of April 29, nearly all listed white liquor companies reported a slowdown in performance for 2024, with six companies experiencing a year-on-year revenue decline [1][4]. - In the first quarter of 2025, nearly half of the white liquor companies reported negative performance, with some experiencing revenue declines of 20% to 30% [1][12]. - The total revenue of all white liquor companies in 2024 exceeded 440 billion yuan, primarily driven by growth from leading companies like Moutai [4][7]. Group 2: Market Dynamics - The competitive landscape of the white liquor industry has shifted, with Shanxi Fenjiu rising to the third position among leading brands, indicating a consolidation of market power among top players [2][8]. - Over the past five years, the rankings of the top ten white liquor companies have changed significantly, with new entrants and established brands experiencing shifts in their market positions [10][11]. - The performance of mid-sized and smaller liquor companies has generally been poor, with some facing delisting risks [2][12]. Group 3: Future Outlook - Analysts suggest that the white liquor industry is currently in a "bottoming out" phase, with expectations of continued low performance in the second quarter of 2025 [2][17]. - The core issue facing the industry is weak consumer demand, with a need for companies to connect with younger consumers and explore new market segments [18].

Summary of Key Points Core Viewpoints - The report highlights the ongoing trend of stock suspensions due to delisting risk warnings across multiple companies, indicating a potential downturn in market confidence and stability [2][3][4]. Company Listings - Several companies are scheduled for initial public offerings (IPOs) on April 29, 2025, including Tai Li Technology (301595) and Ze Run New Energy (301636), which may attract investor interest [1]. - The report notes the specific dates for various IPO-related activities, such as inquiry periods and fund unfreezing dates, which are crucial for market participants [1]. Stock Suspension Announcements - Numerous companies, including Guohua Network Security (000004) and Nanhua Biology (000504), have announced stock suspensions due to delisting risk warnings, reflecting a significant concern regarding their financial health [2][3]. - The report lists a total of 30 companies facing stock suspensions on April 29, 2025, due to various risk warnings, which may impact investor sentiment and trading volumes [2][3][4]. Special Suspensions - Companies like *ST Xu Lan (000040) and *ST Gong Zhi (000584) are highlighted for potential termination of listings, indicating severe financial distress and regulatory scrutiny [4][5]. - The report emphasizes the importance of monitoring these companies as their situations evolve, which could present both risks and opportunities for investors [4][5].

Core Viewpoint - Qinghai Spring (600381.SH) is facing a delisting risk due to financial indicators triggering delisting clauses, with a warning of "ST" (Special Treatment) to be implemented after the 2024 annual report disclosure [1][2]. Financial Performance - The company expects a net profit loss attributable to shareholders of between 187 million to 225 million yuan for 2024, with a revenue forecast of approximately 256 million to 285 million yuan [2]. - The revenue has been revised down from an initial forecast of 310 million to 339 million yuan to below 300 million yuan, which is critical as it is below the 300 million yuan threshold that could trigger delisting [3][4]. Audit and Regulatory Concerns - The initial financial forecast was questioned by the Shanghai Stock Exchange, leading to an inquiry regarding the authenticity of revenue and the nature of business income [4]. - The auditing firm has raised doubts about the credibility of Qinghai Spring's financial statements, indicating potential for a disclaimer or adverse opinion on the 2024 financial report if sufficient audit evidence cannot be obtained [4][5]. Sales and Revenue Issues - Concerns have been raised regarding the sales of Cordyceps, with reported sales of approximately 152 million yuan, but significant accounts receivable of 56.87 million yuan, suggesting issues with the sales model [5]. - The white liquor segment showed abnormal revenue growth in December, accounting for about 50% of annual sales, which is deemed lacking commercial rationale given the overall market conditions [6][7]. Customer Transactions and Revenue Recognition - The company has been scrutinized for recognizing sales revenue from customers who have not yet sold the products, raising questions about the legitimacy of reported sales figures [7][8]. - Specific customers, such as Chengdu Tinghua Ling, reported significant sales but had not achieved corresponding sales post-delivery, indicating potential revenue recognition issues [9][10]. Conclusion - The discrepancies in reported sales figures and the ongoing audit concerns suggest that the financial health of Qinghai Spring is under significant scrutiny, with the upcoming annual report expected to provide further clarity on these issues [12].

一、 独立董事基本情况 青海春天药用资源科技股份有限公司 独立董事高学敏 2024 年度述职报告 作为青海春天药用资源科技股份有限公司（以下简称"公司"）的独立董事， 本人严格按照《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 独立董事管理办法》、《公司章程》、《公司独立董事工作制度》等相关法律、法规、 规章的规定和要求，在 2024 年度任职期间诚实、勤勉、独立的履行职责,积极出 席相关会议,认真审议董事会各项议案,对公司重大事项发表了独立意见,切实维 护了公司和股东尤其是中小股东的利益, 较好地发挥了独立董事的作用。现就本 人 2024 年度履行独立董事职责情况汇报如下： （一）个人情况 本人高学敏，1938 年出生，中国国籍，无境外居留权，现任北京中医药大学 教授、博士生导师，自 2020 年 6 月开始担任公司第八届董事会独立董事，2023 年 5 月连任公司第九届董事会独立董事，担任战略发展委员会、审计委员会、提 名委员会、薪酬与考核委员会委员。除了青海春天外，报告期内本人还担任湖南 方盛制药股份有限公司独立董事。 （二）是否存在影响独立性的情况说明 本人和本人的配偶、父母、子女及主 ...

青海春天药用资源科技股份有限公司 独立董事宋玉琦 2024 年度述职报告 公司董事会： 本人是青海春天药用资源科技股份有限公司（以下简称"公司"）第九届董 事会独立董事宋玉琦，在 2024 年能严格按照《公司法》《证券法》《上市公司治 理准则》《上市公司独立董事管理办法》、上海证券交易所《股票上市规则》《上 市公司自律监管指引第 1 号——规范运作》等法律法规、规范性文件以及公司 《章程》《独立董事管理及工作制度》的规定和要求，本着客观、公正、独立的 立场，勤勉尽责地开展相关工作，维护了公司和中小投资者的利益。 现将 2024 年度履职情况报告如下： 一、独立董事基本情况 （一）个人情况 本人宋玉琦，中国国籍，无境外永久居留权，本科学历，注册会计师、资产 评估师。熟悉国内会计准则及相关的财务、税务、审计工作， 2016 年至今担任 北京敬信会计师事务所有限公司副总经理，自 2023 年 5 月 30 日开始担任公司独 立董事，同时担任公司董事会战略发展委员会委员、薪酬与考核委员会召集人、 审计委员会和独立董事专门会议召集人。 （二）是否存在影响独立性的情况说明 本人和本人的父母及主要社会关系均未在公司或公司附 ...